Clinical characteristics were compared between B-ALL and MPAL with <i>TCF3-ZNF384</i> fusion.<h4>Results</h4>The relapsed lymphoblasts showed moderate sensitivity to both acute myelocytic leukemia (AML) - and acute lymphoblastic leukemia (ALL)-directed combination chemotherapy schemes, as well as to multiple targeted therapeutic drugs. This evidence concerns the gene ZNF384 and acute lymphoblastic leukemia.